ACE 083

Drug Profile

ACE 083

Alternative Names: ACE-083

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Acceleron Pharma
  • Class Recombinant fusion proteins
  • Mechanism of Action TGF-beta superfamily protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Facioscapulohumeral muscular dystrophy
  • Phase I Inclusion body myositis

Most Recent Events

  • 16 Mar 2017 Acceleron plans a phase II trial in Charcot-Marie-Tooth disease (Parenteral)
  • 29 Nov 2016 Phase-II clinical trials in Facioscapulohumeral muscular dystrophies in USA (IM) (NCT02927080)
  • 04 Aug 2016 Acceleron Pharma plans a phase II trial for facioscapulohumeral muscular dystrophy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top